-$0.25 EPS Expected for Lipocine Inc (LPCN) This Quarter
Analysts expect Lipocine Inc (NASDAQ:LPCN) to post earnings per share (EPS) of ($0.25) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Lipocine’s earnings, with estimates ranging from ($0.28) to ($0.22). Lipocine reported earnings per share of ($0.22) during the same quarter last year, which would indicate a negative year-over-year growth rate of 13.6%. The company is expected to issue its next quarterly earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Lipocine will report full year earnings of ($0.80) per share for the current financial year, with EPS estimates ranging from ($1.00) to ($0.62). For the next financial year, analysts expect that the business will post earnings of ($0.47) per share, with EPS estimates ranging from ($0.98) to $0.24. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Lipocine.
Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.10.
NASDAQ:LPCN traded down $0.06 during trading hours on Friday, hitting $1.57. The company’s stock had a trading volume of 68,983 shares, compared to its average volume of 65,253. The firm has a market capitalization of $34.66 million, a PE ratio of -1.50 and a beta of 0.49. The company has a debt-to-equity ratio of 0.62, a current ratio of 8.89 and a quick ratio of 8.89. Lipocine has a 52-week low of $1.03 and a 52-week high of $4.38.
Lipocine Company Profile
Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.
See Also: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.